Cited by 6,670Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Osteoclast differentiation and activation

Boyle, William J., Simonet, W. Scott, Lacey, David L.·2003·Nature

Open this paper in CoChat — free account

Abstract

Osteoclasts are specialized cells derived from the monocyte/macrophage haematopoietic lineage that develop and adhere to bone matrix, then secrete acid and lytic enzymes that degrade it in a specialized, extracellular compartment. Discovery of the RANK signalling pathway in the osteoclast has provided insight into the mechanisms of osteoclastogenesis and activation of bone resorption, and how hormonal signals impact bone structure and mass. Further study of this pathway is providing the molecular basis for developing therapeutics to treat osteoporosis and other diseases of bone loss.

Integrity signals

Registry

Crossref · 10.1038/nature01658

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citation
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citation
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citation
Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Self-citation
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z. (2002) · Nature reviews. Cancer · doi:10.1038/nrc780 · Cited by 2,476
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Self-citation

Flagged first, then by citations

Show all 77 references

Sorted by citations

Items 401–500 of 1,034

(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis
den Uyl, D., Nurmohamed, M. T., van Tuyl, L. H. D., Raterman, H. G., & Lems, W. F. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3224 · Cited by 139
“directly through an induction of osteoclastogenesis or through the OPG pathway [116,131].”
Background
Antibacterial surface modification of titanium implants in orthopaedics
Orapiriyakul, W., Young, P. S., Damiati, L. A., & Tsimbouri, P. M. (2018) · Journal of Tissue Engineering · doi:10.1177/2041731418789838 · Cited by 139
Are Oxidative Stress and Inflammation Mediators of Bone Loss Due to Estrogen Deficiency? A Review of Current Evidence
Mohamad, N.-V., Soelaiman, I. N., & Chin, K. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200604160614 · Cited by 142
Genetic and Transcriptional Control of Bone Formation
Javed, A., Chen, H., & Ghori-Javed, F. Y. (2010) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2010.05.001 · Cited by 143
“Macrophage colony stimulating factor (M-CSF) and the RANKL, the two cytokines produced by osteoblasts are essential and sufficient for osteoclastogenesis (82).”
Background
Ovarian Aging and Osteoporosis
Li, L., & Wang, Z. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_13 · Cited by 138
Severity of obstructive airway disease and risk of osteoporotic fracture
de Vries, F., van Staa, T. P., Bracke, M., Cooper, C. C., Leufkens, H. G. M., & Lammers, J. J. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00058204 · Cited by 136
Extracellular Nucleotides Act Through P2X7 Receptors to Activate NF-κB in Osteoclasts
Korčok, J., Raimundo, L., Ke, H. Z., Sims, S. M., & Dixon, S. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040108 · Cited by 138
“RANKL, a TNF-related trimeric cell surface protein, is synthesized by stromal cells, osteoblasts, and activated lymphocytes.((1)) RANKL binds to its receptor RANK, a member of the TNF receptor superfamily, to stimulate osteoclastogenesis and activate bone resorption.”
Background
Clinical development of anti-RANKL therapy
Schwarz, E. M., & Ritchlin, C. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2171 · Cited by 138
“RANK-Fc and OPG-Fc proved to be very specific and effective inhibitors, and essentially all published preclinical studies to date have used these recombinant proteins [3].”
Background
Osteoclast stimulatory transmembrane protein (OC‐STAMP), a novel protein induced by RANKL that promotes osteoclast differentiation
Yang, M., Birnbaum, M. J., MacKay, C. A., Mason‐Savas, A., Thompson, B., & Odgren, P. R. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21331 · Cited by 140
“Osteoclast precursors respond to signals from colony-stimulating factor-1 (CSF-1; M-CSF) and express RANK, the receptor for the TNF superfamily member RANKL (TRANCE,OPGL,ODF)(Boyle et al., 2003).”
Background
Liposomal clodronate inhibition of osteoclastogenesis and osteoinduction by submicrostructured beta-tricalcium phosphate
Davison, N. L., Gamblin, A.-L., Layrolle, P., Yuan, H., de Bruijn, J. D., & Groot, F. B. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.013 · Cited by 138
IL-34 and CSF-1: similarities and differences
Nakamichi, Y., Udagawa, N., & Takahashi, N. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0476-3 · Cited by 138
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
Bone, H. G., Dempster, D., Eisman, J. A., Greenspan, S. L., McClung, M. R., Nakamura, T., Papapoulos, S. E., Shih, W. J., Rybak-Feiglin, A., Santora, A. C., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2944-6 · Cited by 138
“Osteoclast number and activity are regulated by receptor activator of nuclear factor kappa-B ligand (RANKL), a membrane-bound protein produced by neighboring osteocytes and osteoblasts [7].”
Background
Overview of Glutamatergic Dysregulation in Central Pathologies
Miladinovic, T., Nashed, M. G., & Singh, G. (2015) · Biomolecules · doi:10.3390/biom5043112 · Cited by 145
“cells into the bone microenvironment disrupts this homeostasis, and may contribute to CIBP [209–211].”
Background
Chemistry, pharmacokinetics, pharmacological activities, and toxicity of Quercitrin
Chen, J., Li, G., Sun, C., Peng, F., Yu, L., Chen, Y., Tan, Y., Cao, X., Tang, Y., Xie, X., et al. (2022) · Phytotherapy Research · doi:10.1002/ptr.7397 · Cited by 143
RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulationPreprint
Yang, S., & Li, Y. (2007) · Genes & Development · doi:10.1101/gad.1544107 · Cited by 138
“The binding of receptor activator of nuclear factor B (NF- B) ligand (RANKL) to its receptor, RANK, results in the recruitment of tumor ne- crosis factor (TNF) receptor-associated factor 6 (TRAF6), which activates the NF- B, c-Fos, Jun N-terminal kinase (JNK), and p38 pathways (Boyle et al. 2003).”
BackgroundInfluential
Soluble ions more than particulate cobalt‐alloy implant debris induce monocyte costimulatory molecule expression and release of proinflammatory cytokines critical to metal‐induced lymphocyte reactivity
Caicedo, M. S., Pennekamp, P. H., McAllister, K., Jacobs, J. J., & Hallab, N. J. (2009) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32627 · Cited by 138
Structural and Functional Insights of RANKL–RANK Interaction and Signaling
Liu, C., Walter, T. S., Huang, P., Zhang, S., Zhu, X., Wu, Y., Wedderburn, L. R., Tang, P., Owens, R. J., Stuart, D. I., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904033 · Cited by 142
A TNF receptor loop peptide mimic blocks RANK ligand–induced signaling, bone resorption, and bone loss
Aoki, K., Saito, H., Itzstein, C., Ishiguro, M., Shibata, T., Blanqué, R., Mian, A. H., Takahashi, M., Suzuki, Y., Yoshimatsu, M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci22513 · Cited by 136
Untitled work
(2005) · PubMed · Cited by 135
Inhibition of Osteoclast Differentiation by Gold Nanoparticles Functionalized with Cyclodextrin Curcumin Complexes
Heo, D. N., Ko, W., Moon, H., Kim, H., Lee, S. J., Lee, J. B., Bae, M. S., Yi, J.-K., Hwang, Y., Bang, J. B., et al. (2014) · ACS Nano · doi:10.1021/nn504329u · Cited by 135
An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption
Herrera, B. S., Ohira, T., Gao, L., Omori, K., Yang, R., Zhu, M., Muscará, M. N., Serhan, C. N., Dyke, T. E. V., & Gyurko, R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.367 · Cited by 135
“…is a permissive factor necessary in early cell-fate determination, whereas RANKL is the final mediator of many physiological regulators of bone resorption (such as parathyroid hormone, calcitonin and calcitriol) and is an obligatory factor for OC differentiation and survival (Boyle et al., 2003).”
BackgroundInfluential
Epigallocatechin-3-gallate Inhibits Osteoclastogenesis by Down-Regulating c-Fos Expression and Suppressing the Nuclear Factor-κB Signal
Lee, J.-H., Hexiu, J., Shim, H., Kim, H., Ha, H., & Lee, Z. H. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.057877 · Cited by 135
“Bone homeostasis depends on maintaining a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts (Boyle et al., 2003).”
Background
The multiple faces of autoimmune-mediated bone loss
Schett, G. A., & David, J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.190 · Cited by 135
“Differentiation is governed by two essential cytokines: macrophage colony-stimulating factor that promotes proliferation and survival of the progenitors, and the receptor activator of nuclear factor κB ligand (RANKL)—a member of the tumor necrosis factor (TNF) superfamily that acts via its receptor RANK and the coupli…”
IL‐23 promotes osteoclast formation by up‐regulation of receptor activator of NF‐κB (RANK) expression in myeloid precursor cells
Chen, L., Wei, X., Evans, B. A. J., Jiang, W. G., & Aeschlimann, D. P. (2008) · European Journal of Immunology · doi:10.1002/eji.200838192 · Cited by 135
Significance of LL‐37 on Immunomodulation and Disease Outcome
Yang, B., Good, D. M., Mosaiab, T., Liu, W., Ni, G., Kaur, J., Liu, X., Jessop, C., Yang, L., Fadhil, R., et al. (2020) · BioMed Research International · doi:10.1155/2020/8349712 · Cited by 137
“RANKL binds to RANK expressed in osteoclast precursors and subsequently induces osteoclast differentiation [129, 130].”
Background
Sequential activation of heterogeneous macrophage phenotypes is essential for biomaterials-induced bone regeneration
Qiao, W., Xie, H., Fang, J., Shen, J., Li, W., Shen, D., Wu, J., Wu, S., Liu, X., Zheng, Y., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121038 · Cited by 137
Cytokine-mediated immunomodulation of osteoclastogenesis
Zhou, P., Zheng, T., & Zhao, B. (2022) · Bone · doi:10.1016/j.bone.2022.116540 · Cited by 148
Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1–haploinsufficient osteoclast functions
Yang, F., Shi, C., Robling, A. G., Yu, X., Nebesio, T. D., Yan, J., Morgan, T., Li, X., Yuan, J., Hock, J. M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29092 · Cited by 134
“Following adhesion, osteoclasts form a specialized cell–extracellular matrix to initiate degradation of bone matrix by secreting proteinases (6).”
BackgroundInfluential
Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors
Deng, G., Zheng, L., Chan, F. K.-M., & Lenardo, M. J. (2005) · Nature Medicine · doi:10.1038/nm1304 · Cited by 134
The role of MicroRNAs in Osteoclasts and Osteoporosis
Tang, P., Xiong, Q., Ge, W., & Zhang, L. (2014) · RNA Biology · doi:10.1080/15476286.2014.996462 · Cited by 135
“Osteoclasts, the sole cell type capable of bone resorption in the human body, originate from haematopoietic progenitors which can also differentiate into monocytes and macrophages.(2) The process of osteoclast differentiation is regulated by a variety of cytokines, growth factors and hormones, including M-CSF, RANKL,…”
Background
New insights into the pathogenesis and genetics of psoriatic arthritis
Nograles, K. E., Brasington, R., & Bowcock, A. M. (2009) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0987 · Cited by 133
Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway
Akiyama, T., Dass, C. R., & Choong, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0530 · Cited by 137
“osteoclast-specific protease and one of the main enzymes responsible for the bone resorption (17, 26).”
Background
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Zauli, G., Corallini, F., Bossi, F., Fabio Fischetti, I., Durigutto, P., Celeghini, C., Tedesco, F., & Secchiero, P. (2007) · Blood · doi:10.1182/blood-2007-01-068395 · Cited by 133
“OPG inhibits osteoclastogenesis by binding to receptor activator of NF-kB ligand (RANKL), a member of the TNF superfamily of cytokines, and preventing the interaction of RANKL with its high-affinity transmembrane receptor namely receptor activator of NF-kB (RANK).(2) It has been shown that in the low nanomolar range,…”
Background
Molecular biology of bone remodelling.
Rucci, N. (2008) · PubMed Central · Cited by 133
Natural products for treatment of bone erosive diseases: The effects and mechanisms on inhibiting osteoclastogenesis and bone resorption
An, J., Hao, D., Zhang, Q., Chen, B., Zhang, R., Wang, Y., & Yang, H. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.04.024 · Cited by 134
Acid Neutralization and Immune Regulation by Calcium–Aluminum-Layered Double Hydroxide for Osteoporosis Reversion
Fu, H., Wang, L., Bao, Q., Ni, D., Hu, P., & Shi, J. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00749 · Cited by 132
Molecular Profiling of Giant Cell Tumor of Bone and the Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor κB
Morgan, T., Atkins, G. J., Trivett, M. K., Johnson, S. A. S., Kansara, M., Schlicht, S., Slavin, J., Simmons, P. J., Dickinson, I. C., Powell, G., et al. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62959-8 · Cited by 134
MyD88 But Not TRIF Is Essential for Osteoclastogenesis Induced by Lipopolysaccharide, Diacyl Lipopeptide, and IL-1α
Sato, N., Takahashi, N., Suda, K., Nakamura, M., Yamaki, M., Ninomiya, T., Kobayashi, Y., Takada, H., Shibata, K., Yamamoto, M., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040689 · Cited by 132
Osteoclasts and odontoclasts: signaling pathways to development and disease
Wang, Z., & McCauley, L. K. (2010) · Oral Diseases · doi:10.1111/j.1601-0825.2010.01718.x · Cited by 132
“The two essential factors that most positively impact osteoclast differentiation are RANKL and macrophage colony stimulating factor (M-CSF) (Boyle et al, 2003).”
Background
Role of mitochondrial reactive oxygen species in osteoclast differentiation
Srinivasan, S., Koenigstein, A., Joseph, J., Sun, L., Kalyanaraman, B., Zaidi, M., & Avadhani, N. G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05377.x · Cited by 132
Regulatory Mechanism of Osteoclastogenesis by RANKL and Wnt Signals
Takahashi, N. (2010) · Frontiers in bioscience · doi:10.2741/3673 · Cited by 132
“We developed a mouse coculture system of osteoblasts/stromal cells and hematopoietic cells in which osteoclasts are formed in response to bone resorptionstimulating factors such as 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3], parathyroid hormone (PTH), prostaglandin E2 (PGE2), and interleukin 11 (IL-11) (1,4).”
BackgroundInfluential
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 131
TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression
Lamora, A., Talbot, J., Mullard, M., Royer, B. B.-L., Rédiní, F., & Verrecchia, F. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5110096 · Cited by 141
“In this context, we demonstrated that Smad7 overexpression in osteosarcoma cells blocks their ability to produce RANKL, a cytokine that plays a central role in osteoclast differentiation and activation [91].”
Background
Regulatory roles and molecular signaling of TNF family members in osteoclasts
Feng, X. (2005) · Gene · doi:10.1016/j.gene.2005.01.014 · Cited by 132
RANK Expression as a Cell Surface Marker of Human Osteoclast Precursors in Peripheral Blood, Bone Marrow, and Giant Cell Tumors of Bone
Atkins, G. J., Kostakis, P., Vincent, C., Farrugia, A. N., Houchins, J. P., Findlay, D. M., Evdokiou, A., & Zannettino, A. C. W. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060604 · Cited by 137
“We also describe the expression of RANK in giant cell tumor of bone (GCT), a confirmed source of both mature human OCs and preOCs.”
BackgroundInfluential
Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease
Kajiya, M., Giro, G., Taubman, M. A., Han, X., Mayer, M. P. A., & Kawai, T. (2010) · Journal of Oral Microbiology · doi:10.3402/jom.v2i0.5532 · Cited by 135
“This OPG-mediated inhibition of ligation between RANKL and RANK then decreases the velocity and intensity of osteoclastogenesis and promotes apoptosis of previously differentiated and activated osteoclasts, thus reducing the process of bone resorption (14).”
Background
Transcription factor C/EBPβ isoform ratio regulates osteoclastogenesis through MafB
Smink, J. J., Bégay, V., Schoenmaker, T., Sterneck, E., de Vries, T. J., & Leutz, A. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.127 · Cited by 130
“Immunohistochemistry of bone tissue revealed C/EBPb protein expression in growth plate chondrocytes (Figure 1A) and in osteoblasts (Figure 1B and C, arrowheads), but not in osteoclasts (Figure 1B, arrow) or osteocytes (Figure 1C, arrows).”
Background
DAP12 Couples c-Fms Activation to the Osteoclast Cytoskeleton by Recruitment of Syk
Zou, W., Reeve, J., Liu, Y.-L., Teitelbaum, S. L., & Ross, F. P. (2008) · Molecules and Cells · doi:10.1016/j.molcel.2008.06.023 · Cited by 143
“Osteoclasts, which are the exclusive resorptive cells of the skeleton, differentiate within the bone environment from members of the macrophage lineage under the control of M-CSF and RANK ligand (RANKL) (Boyle et al., 2003; Teitelbaum and Ross, 2003).”
Background
Prostaglandin E2 Enhances Osteoclastic Differentiation of Precursor Cells through Protein Kinase A-dependent Phosphorylation of TAK1
Kobayashi, Y., Mizoguchi, T., Take, I., Kurihara, S., Udagawa, N., & Takahashi, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411189200 · Cited by 137
Gut microbiota-bone axis
Villa, C., Ward, W. E., & Comelli, E. M. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1010034 · Cited by 132
“Both M-CSF and RANKL are expressed by stromal cells found in the bone marrow, and also in osteoblasts, in response to cytokines and hormones that stimulate bone resorption (Boyle et al., 2003).”
Osteoclast differentiation and gene regulation
Zhao, Q. (2006) · Frontiers in bioscience · doi:10.2741/2252 · Cited by 129
“Intracellular RANK signaling by its interaction with RANKL induces recruitment and activation of cytoplasmic tumor necrosis factor receptor-associated factors (TRAFs), leading to the activation of multiple signaling cascades such as MAP, NF-κB, Src, and Akt (31).”
Influential
The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I
Kawatani, M., Okumura, H., Honda, K., Kanoh, N., Muroi, M., Dohmae, N., Takami, M., Kitagawa, M., Futamura, Y., Imoto, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712239105 · Cited by 128
“During resorption, osteoclasts are highly polarized; form tightly sealed compartments on the bone surface; and secrete protons and proteases such as cathepsin K from the ruffled border; resulting in the degradation of bone matrix (1).”
Background
Myeloma cells suppress osteoblasts through sclerostin secretion
Colucci, S. C., Brunetti, G., Oranger, A., Mori, G., Sardone, F., Specchia, G., Rinaldi, E., Curci, P., Liso, V., Passeri, G., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.22 · Cited by 130
Calcium signaling in osteoclasts
Hwang, S., & Putney, J. W. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.11.002 · Cited by 131
Differential effect of hydroxyapatite nano-particle versus nano-rod decorated titanium micro-surface on osseointegration
Bai, L., Liu, Y., Du, Z., Weng, Z., Yao, W., Zhang, X., Huang, X., Yao, X., Crawford, R., Hang, R., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.06.023 · Cited by 129
Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw
Chang, J., Hakam, A. E., & McCauley, L. K. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0474-4 · Cited by 134
Myeloma bone disease: Pathophysiology and management
Silbermann, R. W., & Roodman, G. D. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.04.001 · Cited by 135
“RANKL expression is induced by cytokines that stimulate bone resorption [45] such as PTH, 1,25OH Vitamin D3, prostaglandins [46,47], and myeloma cells themselves both produce and induce production of RANKL by marrow stromal cells via adhesive interactions described above, as well as by soluble factors produced by myel…”
Background
The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology
Zauli, G., & Secchiero, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.04.002 · Cited by 129
“OPG can bind to RANKL, an additional member of the TNF superfamily, and prevent interaction with its cognate receptor, termed receptor activator of NF-kB (RANK), a member of the TNF receptor superfamily (reviewed in [16]); however, OPG can also interact with TRAIL showing a comparable affinity to that of transmembrane…”
BackgroundResultInfluential
Bone Biology and Physiology
Buck, D. W., & Dumanian, G. A. (2012) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e31824eca94 · Cited by 128
Intracellular and Extracellular ATP Coordinately Regulate the Inverse Correlation between Osteoclast Survival and Bone Resorption
Miyazaki, T., Iwasawa, M., Nakashima, T., Mori, S., Shigemoto, K., Nakamura, H., Katagiri, H., Takayanagi, H., & Tanaka, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.385369 · Cited by 129
“Osteoclasts are large, multinucleated, motile cells that are formed by fusion of hematopoietic cells of monocyte/macrophage lineage (1, 2).”
Background
Nanozymes for Regenerative Medicine
Mou, X., Wu, Q., Zhang, Z., Liu, Y., Zhang, J., Zhang, C., Chen, X., Fan, K., & Liu, H. (2022) · Small Methods · doi:10.1002/smtd.202200997 · Cited by 127
Murine and Chicken Chondrocytes Regulate Osteoclastogenesis by Producing RANKL in Response to BMP2
Usui, M., Xing, L., Drissi, H., Zuscik, M. J., O’Keefe, R. J., Chen, D., & Boyce, B. F. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071025 · Cited by 129
“resorb mineralized matrix and are formed by fusion of hematopoietic precursor cells in the monocyte/macrophage lineage.((2)) Osteoclast formation requires the expression of RANKL by supporting cells, such as marrow stromal cells, osteoblasts, and T cells,((3)) and of RANK, a member of the TNF receptor family, by osteo…”
Background
Osteoclasts Control Osteoblast Chemotaxis via PDGF-BB/PDGF Receptor Beta Signaling
Sanchez-Fernandez, M. A., Gallois, A., Riedl, T., Jurdic, P., & Hoflack, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003537 · Cited by 130
“osteoclastogenesis, are now established [3].”
Calcification and Cardiovascular Health
Ketteler, M., Schlieper, G., & Floege, J. (2006) · Hypertension · doi:10.1161/01.hyp.0000219635.51844.da · Cited by 130
miR-29 Promotes Murine Osteoclastogenesis by Regulating Osteoclast Commitment and Migration
Franceschetti, T., Kessler, C. B., Lee, S., & Delany, A. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.484568 · Cited by 127
“The differentiation of osteoclasts from hematopoietic precursors is a complex multistep process (1).”
Background
Erk1 Positively Regulates Osteoclast Differentiation and Bone Resorptive Activity
He, Y., Staser, K. W., Rhodes, S. D., Liu, Y., Wu, X., Park, S.-J., Yuan, J., Yang, X., Li, X., Jiang, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024780 · Cited by 130
“Though bisphosphonates have been the cornerstone of osteoporosis therapy since the 1960’s, recent work has focused on more selective compounds [45].”
Background
Gα13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3β-NFATc1 signalling pathway
Wu, M., Chen, W., Lü, Y., Zhu, G., Hao, L., & Li, Y. (2017) · Nature Communications · doi:10.1038/ncomms13700 · Cited by 126
Collagen Type I as a Ligand for Receptor-Mediated Signaling
Boraschi-Diaz, I., Wang, J. P., Mort, J. S., & Komarova, S. V. (2017) · Frontiers in Physics · doi:10.3389/fphy.2017.00012 · Cited by 125
“Concomitantly, proteolytic enzymes are released to digest the organic matrix [83, 84].”
Background
Influence of the TGF-β Superfamily on Osteoclasts/Osteoblasts Balance in Physiological and Pathological Bone Conditions
Jann, J., Gascon, S., Roux, S., & Faucheux, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207597 · Cited by 133
“Then, they finally undergo maturation after adhesion to bone, in order to become polarized active osteoclasts that can form resorption lacunae [42].”
Background
Insights into Oxidative Stress in Bone Tissue and Novel Challenges for Biomaterials
Cerqueni, G., Scalzone, A., Licini, C., Gentile, P., & Mattioli‐Belmonte, M. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112433 · Cited by 131
Advances in osteoclast biology resulting from the study of osteopetrotic mutations
Segovia‐Silvestre, T., Neutzsky-Wulff, A. V., Sørensen, M. G., Christiansen, C., Bollerslev, J., Karsdal, M. A., & Henriksen, K. (2008) · Human Genetics · doi:10.1007/s00439-008-0583-8 · Cited by 128
Cytosolic Hsp60 Is Involved in the NF-κB-Dependent Survival of Cancer Cells via IKK Regulation
Chun, J. N., Choi, B., Lee, K. W., Lee, D. J., Kang, D. H., Lee, S. Y., Song, I. S., Kim, H. I., Lee, S. H., Kim, H. S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009422 · Cited by 126
“On the other hand, the functional significance of Hsp60-IKKa interaction was also investigated in non-canonical NF-kB signaling, RANK-induced osteoclastogenesis [54].”
Background
In Vivo Fluorescence Imaging of Bone-Resorbing Osteoclasts
Kowada, T., Kikuta, J., Kubo, A., Ishii, M., Maeda, H., Mizukami, S., & Kikuchi, K. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2064582 · Cited by 129
RANKL biology
Takegahara, N., Kim, H., & Choi, Y. (2022) · Bone · doi:10.1016/j.bone.2022.116353 · Cited by 136
Molecular Mechanism of the Bifunctional Role of Lipopolysaccharide in Osteoclastogenesis
Liu, J., Wang, S., Zhang, P., Said-Al-Naief, N. A. H., Michalek, S. M., & Feng, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809789200 · Cited by 128
Epigenetic regulation of osteoclast differentiation: Possible involvement of Jmjd3 in the histone demethylation of Nfatc1
Yasui, T., Hirose, J., Tsutsumi, S., Nakamura, K., Aburatani, H., & Tanaka, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.464 · Cited by 126
“(12,13) The expression of NFATc1 in M-CSF-dependent bone marrow– derived macrophages (BMMs) is upregulated by RANKL stimulation, and NFATc1 subsequently induces a series of osteoclast-specific genes, including cathepsin K, tartrate-resistant acid phosphatase (TRACP), calcitonin receptor, vacuolar type ATPase, osteocla…”
Background
Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function
Hershey, C. L., & Fisher, D. E. (2003) · Bone · doi:10.1016/j.bone.2003.08.014 · Cited by 126
“regulate early events required for osteoclast development [1,2].”
BackgroundInfluential
RANK ligand as a therapeutic target for bone metastases and multiple myeloma
Roodman, G. D., & Dougall, W. C. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.002 · Cited by 127
“Its cognate ligand, RANKL, is expressed almost exclusively within the bone marrow stromal cell compartment and is upregulated by most hormones and factors that stimulate bone resorption (reviewed in [9]).”
Background
WNT signaling in bone development and homeostasis
Zhong, Z. A., Ethen, N. J., & Williams, B. O. (2014) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.159 · Cited by 129
Resolvin E1 and Chemokine-like Receptor 1 Mediate Bone Preservation
Gao, L., Faibish, D., Fredman, G., Herrera, B. S., Chiang, N., Serhan, C. N., Dyke, T. E. V., & Gyurko, R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103688 · Cited by 131
“RANKL is the chief signal for osteoclast differentiation, whereas OPG antagonizes it as a decoy receptor (30).”
Background
Thiram exposure in environment: A critical review on cytotoxicity
Liu, K., Li, Y., Iqbal, M., Tang, Z., & Zhang, H. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.133928 · Cited by 125
Advances in materials-based therapeutic strategies against osteoporosis
Chen, L., Song, J., Li, S., Zhu, Y., Liu, M., Wan, M., 高木, 昭., Tay, F. R., & Niu, L. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122066 · Cited by 127
Inhibitory Immunoglobulin-Like Receptors LILRB and PIR-B Negatively Regulate Osteoclast Development
Mori, Y., Tsuji, S., Inui, M., Sakamoto, Y., Endo, S., Ito, Y., Fujimura, S., Koga, T., Nakamura, A., Takayanagi, H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4742 · Cited by 125
“On the other hand, osteoprotegerin (12), SHIP (13), and SH2 domain-containing tyrosine phosphatase 1 (SHP-1) (14) are suppressive elements for osteoclastogenesis (6), because targeted disruption or naturally occurring loss-of-function mutation of the genes for the secretory protein or one of the intracellular phosphat…”
BackgroundInfluential
GM-CSF Regulates Fusion of Mononuclear Osteoclasts into Bone-Resorbing Osteoclasts by Activating the Ras/ERK Pathway
Lee, M. S., Kim, H. S., Yeon, J., Choi, S., Chun, C. H., Kwak, H. B., & Oh, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804314 · Cited by 126
“Osteoclasts, which are bone-resorbing multinucleated cells, are derived from hematopoietic cells of the monocyte-macrophage lineage by an orchestrated process including cell cycle regulation and cell-cell fusion (3).”
Background
Targeting bone metastases in prostate cancer: improving clinical outcome
Body, J., Casimiro, S., & Costa, L. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.90 · Cited by 124
The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro
Xie, F., Wu, C., Lai, W., Yang, X.-J., Cheung, P.-Y., Yao, X., Leung, P.-C., & Wong, M. (2005) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/neh101 · Cited by 124
“Thus, the effects of HEP on the expression of RANKL and OPG mRNA in UMR 106 cells can be studied to assess its potential effects on osteoclastogenesis.”
BackgroundInfluential
Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients
Jobke, B., Milovanovic, P., Amling, M., & Busse, B. (2014) · Bone · doi:10.1016/j.bone.2013.10.024 · Cited by 123
“Osteoclastogenesis, which includes the development, differentiation and activation of osteoclasts, has been investigated in detail [44,45].”
Background
Andrographolide suppresses RANKL ‐induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo
Zhai, Z., Li, H. W., Liu, G. W., Qu, X., Tian, B., Yan, W., Lin, Z., Tang, T., Qin, A., & Dai, K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12463 · Cited by 123
“…allows the NF-κB proteins (p50, p52 and p65) to enter the nucleus and bind to DNA target sites (Soysa and Alles, 2009), subsequently initiating the expression of certain genes and therefore inducing the formation of functional osteoclasts that are capable of bone resorption (Boyle et al., 2003).”
BackgroundInfluential
Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways
Li, C., Yang, Z., Li, Z., Ma, Y., Zhang, L., Zheng, C., Qiu, W., Wu, X. G., Wang, X., Li, H., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.242 · Cited by 125
Single-cell RNA sequencing deconvolutes the in vivo heterogeneity of human bone marrow-derived mesenchymal stem cells
Wang, Z., Li, X., Yang, J., Gong, Y., Zhang, H., Qiu, X., Liu, Y., Zhou, C., Chen, Y., Greenbaum, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.61950 · Cited by 122
“While osteoclasts are of hematopoietic origin and derived from the “monocyte/macrophagepreosteoclast-osteoclast” differentiation trajectory [1], the detailed origins of osteoblast/osteocyte and chondrocyte are not as well characterized.”
Background
Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling
Thummuri, D., Jeengar, M. K., Shrivastava, S., Nemani, H., Naik, R. R., Chaudhari, P. R., & Naidu, V. G. M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.006 · Cited by 125
“Furthermore, we determined the protein expression of NFATc1 and downstream effector Cathepsin-K.”
BackgroundInfluential
Impact of Bone Harvesting Techniques on Cell Viability and the Release of Growth Factors of Autografts
Miron, R. J., Gruber, R., Hedbom, E., Saulačić, N., Zhang, Y., Sculean, A., Bosshardt, D. D., & Buser, D. (2012) · Clinical Implant Dentistry and Related Research · doi:10.1111/j.1708-8208.2012.00440.x · Cited by 123
Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells
Hou, G., Guo, C., Song, G., Fang, N., Fan, W., CHEN, X.-D., Yuan, L., & Wang, Z. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1406 · Cited by 126
“We also aimed to clarify the mechanism of LPS on MAPK phosphorylation, as well as on the expression of RANK/TRAF6 and COX-2 in preosteoclasts.”
BackgroundInfluential
Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing
Adami, S., Libanati, C. R., Boonen, S., Cummings, S. R., Ho, P., Wang, A., Siris, E. S., & Lane, J. M. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.00774 · Cited by 124
NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases
Lin, T., Pajarinen, J., Lu, L. Y., Nabeshima, A., Córdova, L. A., Yao, Z., & Goodman, S. B. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.11.002 · Cited by 123
“fundamental roles of NF-κB activation in OC differentiation and activation are well defined (Boyle et al., 2003).”
BackgroundInfluential
Review of Integrin‐Targeting Biomaterials in Tissue Engineering
Dhavalikar, P., Robinson, A., Lan, Z., Jenkins, D. M. R., Chwatko, M., Salhadar, K., Jose, A., Kar, R., Shoga, E., Kannapiran, A., et al. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000795 · Cited by 127
Functional Scaffolds for Bone Tissue Regeneration: A Comprehensive Review of Materials, Methods, and Future Directions
Todd, E. A., Mirsky, N. A., Silva, B. L. G., Shinde, A. R., Arakelians, A. R. L., Nayak, V. V., Marcantonio, R. A. C., Gupta, N., Witek, L., & Coelho, P. G. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15100280 · Cited by 130
Cluster analysis and gene expression profiles: A cDNA microarray system-based comparison between human dental pulp stem cells (hDPSCs) and human mesenchymal stem cells (hMSCs) for tissue engineering cell therapy
Yamada, Y. M. A., Fujimoto, A., Itô, A., Yoshimi, R., & Ueda, M. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.02.009 · Cited by 122
Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization.
Ito, Y., Teitelbaum, S. L., Zou, W., Zheng, Y., Johnson, J. F., Chappel, J., Ross, F. P., & Zhao, H.-B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39650 · Cited by 120
Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease
Boyce, B. F., Schwarz, E. M., & Xing, L. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000231913.32364.32 · Cited by 123

Authors: Boyle, W. J., Simonet, W. S., & Lacey, D. L.
Affiliations: Amgen (United States) (US)
Corresponding author: Boyle, William J.
ORCID: Boyle, William J.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2003-05
Volume: 423
Issue: 6937
Pages: 337-342
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature01658
OpenAlex: W2093252878
Cited by: 6,670
References: 77
Citations by year: 2026: 240 · 2025: 269 · 2024: 294 · 2023: 357 · 2022: 349 · 2021: 404 · 2020: 376 · 2019: 381 · 2018: 371 · 2017: 324 · 2016: 311 · 2015: 332 · 2014: 352 · 2013: 315 · 2012: 336
FWCI: 11.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords: osteoclasts, osteoclastogenesis, bone resorption, monocyte/macrophage lineage, bone matrix degradation, hormonal regulation of bone, osteoporosis
MeSH terms: Animals, Bone Resorption, Carrier Proteins, Cell Differentiation, Glycoproteins, Humans, Membrane Glycoproteins, Osteoclasts, Osteoporosis, Signal Transduction, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteoclast differentiation and activation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks